Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Popular weight loss medications like Ozempic can help reverse low testosterone levels in men with obesity or Type 2 diabetes, ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.